- Home
- NFGC vs ALDX Comparison
NFGC vs ALDX Comparison
Compare NFGC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFGC
- ALDX
- Stock Information
- Founded
- NFGC 2016
- ALDX 2004
- Country
- NFGC Canada
- ALDX United States
- Employees
- NFGC N/A
- ALDX N/A
- Industry
- NFGC Precious Metals
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- NFGC Basic Materials
- ALDX Health Care
- Exchange
- NFGC Nasdaq
- ALDX Nasdaq
- Market Cap
- NFGC 364.6M
- ALDX 342.3M
- IPO Year
- NFGC N/A
- ALDX 2014
- Fundamental
- Price
- NFGC $2.04
- ALDX $4.96
- Analyst Decision
- NFGC Strong Buy
- ALDX Strong Buy
- Analyst Count
- NFGC 1
- ALDX 2
- Target Price
- NFGC $5.00
- ALDX $9.50
- AVG Volume (30 Days)
- NFGC 1.4M
- ALDX 794.0K
- Earning Date
- NFGC 11-11-2025
- ALDX 11-06-2025
- Dividend Yield
- NFGC N/A
- ALDX N/A
- EPS Growth
- NFGC N/A
- ALDX N/A
- EPS
- NFGC N/A
- ALDX N/A
- Revenue
- NFGC N/A
- ALDX N/A
- Revenue This Year
- NFGC N/A
- ALDX N/A
- Revenue Next Year
- NFGC N/A
- ALDX $63.48
- P/E Ratio
- NFGC N/A
- ALDX N/A
- Revenue Growth
- NFGC N/A
- ALDX N/A
- 52 Week Low
- NFGC $0.93
- ALDX $1.14
- 52 Week High
- NFGC $2.89
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- NFGC 62.67
- ALDX 34.88
- Support Level
- NFGC $1.78
- ALDX $5.48
- Resistance Level
- NFGC $2.19
- ALDX $5.88
- Average True Range (ATR)
- NFGC 0.13
- ALDX 0.30
- MACD
- NFGC 0.02
- ALDX -0.12
- Stochastic Oscillator
- NFGC 73.68
- ALDX 1.62
About NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.